TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall duration of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: on-treatment composite end point event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean estimated 1-year on-treatment combined end point cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mortality rates in women younger than 60 years
Endpoint domain: Mortality/survival
Primary endpoint: risk of secondary cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse-free survival rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Ham-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OQ-45.2 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indicators of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMPG 0/1 perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cTnI levels after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average rating of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐chosen walking velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint moments (hip extension, knee flexion, plantar flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cure of pelvic prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: recurrent tonsillitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in 6MWT distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dependencies in activities of daily living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CVD risk correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-compliance with routine cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean increase in HAI titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bishop's score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chances of vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglycerides (Tg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: M value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean pain score after biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer's test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Grade 3 or greater treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: successful extubation outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in overall reflective TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in instantaneous TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life variables in patients with SAR
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean percentage of the reduced defect height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage area of the reduced defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of clinical relapse of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription of prophylactic antiemetics for OINV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VL <200 copies/mL at 96 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cardiac rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of all-cause mortality, re-infarction, or disabling stroke at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Release of lactate in the coronary sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Release of hypoxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10-year estimated coronary heart disease death rate
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of duodenal ulcer development
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of gastric ulcer development
Endpoint domain: Adverse events/effects
Primary endpoint: eGFRcys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VAS scores after catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Leucine Ra (indicator of protein breakdown)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leucine Ox (indicator of protein breakdown)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: slope of the reciprocal serum creatinine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: carotid artery IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autoregulatory Index (ARI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine albumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SGRQ Symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood antioxidant levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood oxidant levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: initiation of osteoporosis treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rates of new FF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median percent change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: exercise behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-CABG major bleeding (MB)
Endpoint domain: Adverse events/effects
Primary endpoint: Ki-67-positive cells/total nuclei ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative total protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Documentation of advance directives
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Discussion of resuscitation preferences with physician
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Nesfatin-1 secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC H2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom severities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in salivary mutans streptococci counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower-urinary symptoms of pain, urgency, and dysuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Partial response (PR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fasting serum glucose reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants reaching HbA1c level of <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment success
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FEV1 (absolute values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days to recovery of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: decrease in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean serum glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: understanding of medical condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum triacylglycerols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: health-related quality of life (SF-36) scores in bodily pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: health-related quality of life (SF-36) scores in role limitation owing to emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: NRS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional infiltration of local anaesthetic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pressure in tractioned spines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of tumors classified as low risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: acute withdrawal symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of PAI‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Circulating levels of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Circulating levels of IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of gastric cancer (GC)
Endpoint domain: Mortality/survival
Primary endpoint: Pain evaluated by visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly stress incontinence prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: weekly urge incontinence prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Participation rate in the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of oxygen and ventilatory support use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean middle cerebral artery blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: platelet function analyzer closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean percentage change in central foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte counts normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of TMD pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zone of acceptability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retrusive to protrusive and protrusive to retrusive excursions measured in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal absorption of minerals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: immediate reduction in severity rating of the SP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Checklist pass rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hands-on time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Self-assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: eGFR stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year event free survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: 5-year relapse-free survival rate (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: earlier resolution of ST-segment elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurocognitive function (verbal memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients reaching A1C <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen consumption (VO2) peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasodilatory response to ACh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of renal function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Spot urinary albumin-to-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy in detecting hepatic metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taking adherence regarding puff inhalers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing adherence of inhaled medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: error reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of care improvement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Improvement in machine-guarding practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in safety audit scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLAM score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLEDAI score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at the surgical site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal side effects (abdominal distension and diarrhea)
Endpoint domain: Adverse events/effects
Primary endpoint: Function improvement (BASFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity improvement (BASDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of atrial and ventricular effective refractory periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complication rate after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Postvoid residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Skin pigmentation increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Transient erythema
Endpoint domain: Adverse events/effects
Primary endpoint: 21-day mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: incidence of dialysis therapy
Endpoint domain: Mortality/survival
Primary endpoint: time to recurrent stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with pH <= 2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric volume retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preventing repeated hospitalization for ARI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Balance and lower extremity muscle power improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported recreational computer use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedentary activities summed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS-depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOSIE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in inflammatory and noninflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in acne severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aesthetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: biochemical progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: clinical progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: cumulative rate of loco-regional failure
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects achieving HbA(1c) <= 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of hospitalization for febrile neutropenia
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival at three years
Endpoint domain: Mortality/survival
Primary endpoint: Number of severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative nutrition indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MRI remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of artificial ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time in intensive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: recurrence of mood episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No demonstrable motor block after the first hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Treatment Failure (TTF)
Endpoint domain: Mortality/survival
Primary endpoint: Nurses' attitude to reporting errors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reporting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total rosacea severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: modified-Yale Preoperative Anxiety Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes